OptimizeRx (OPRX) announced organizational updates and leadership advancements designed to accelerate the Company’s Rule of 40 strategy-balancing sustained growth with increased profitability. Ed Stelmakh has been appointed Chief Financial & Strategic Officer; Marion Odence-Ford has been named Chief Legal & Administrative Officer; Brendan Merrell has been appointed Chief Operating Officer; Andy D’Silva has been promoted to Chief Business Officer
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OPRX:
- OptimizeRx Earnings Call: Strong Growth and Positive Outlook
- OptimizeRx price target raised to $20 from $14 at Citizens JMP
- OptimizeRx Reports Strong Q2 2025 Financial Growth
- OptimizeRx price target raised to $27 from $22 at Roth Capital
- OptimizeRx: Strong Q2 Performance and Upgraded Guidance Justify Buy Rating